A semi-quantitative upconversion nanoparticle-based immunochromatographic assay for SARS-CoV-2 antigen detection
Frontiers in Microbiology · 11.12.2023 · 14
DOI: 10.3389/fmicb.2023.1289682 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Microbiology, online erschienen am 11.12.2023. Verfasst von Hai Ding und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, Jiangsu, China. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The unprecedented public health and economic impact of the coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been met with an equally unprecedented scientific response. Sensitive point-of-care methods to detect SARS-CoV-2 antigens in clinical specimens are urgently required for the rapid screening of individuals with viral infection. Here, we developed an upconversion nanoparticle-based lateral flow immunochromatographic assay (UCNP-LFIA) for the high-sensitivity detection of SARS-CoV-2 nucleocapsid (N) protein. A pair of rabbit SARS-CoV-2 N-specific monoclonal antibodies was conjugated to UCNPs, and the prepared UCNPs were then deposited into the LFIA test strips for detecting and capturing the N protein. Under the test conditions, the limit of detection (LOD) of UCNP-LFIA for the N protein was 3.59 pg/mL, with a linear range of 0.01–100 ng/mL. Compared with that of the current colloidal gold-based LFIA strips, the LOD of the UCNP-LFIA-based method was increased by 100-fold. The antigen recovery rate of the developed method in the simulated pharyngeal swab samples ranged from 91.1 to 117.3%. Furthermore, compared with the reverse transcription-polymerase chain reaction, the developed UCNP-LFIA method showed a sensitivity of 94.73% for 19 patients with COVID-19. Thus, the newly established platform could serve as a promising and convenient fluorescent immunological sensing approach for the efficient screening and diagnosis of COVID-19.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Laboratory Medicine, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, Jiangsu, China.
- Department of Clinic Nutrition, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China.
- Polariton Life Technologies Ltd., Soochow, Jiangsu, China.
Zitieren
APA
Ding, H., Zhang, W., Wang, S. A., Li, C., Li, W., Liu, J., Yu, F., Tao, Y., Cheng, S., Xie, H., & Chen, Y. (2023). A semi-quantitative upconversion nanoparticle-based immunochromatographic assay for SARS-CoV-2 antigen detection. Frontiers in Microbiology, 14. https://doi.org/10.3389/fmicb.2023.1289682
Vancouver
Ding H, Zhang W, Wang SA, Li C, Li W, Liu J, et al. A semi-quantitative upconversion nanoparticle-based immunochromatographic assay for SARS-CoV-2 antigen detection. Frontiers in Microbiology. 2023;14. doi:10.3389/fmicb.2023.1289682
BibTeX
@article{Ding2023,
author = {Ding, Hai and Zhang, Wanying and Wang, Shu-An and Li, Chuang and Li, Wanting and Liu, Jing and Yu, Fang and Tao, Yanru and Cheng, Siyun and Xie, Hui and Chen, Yuxin},
title = {A semi-quantitative upconversion nanoparticle-based immunochromatographic assay for SARS-CoV-2 antigen detection},
journal = {Frontiers in Microbiology},
year = {2023},
volume = {14},
doi = {10.3389/fmicb.2023.1289682}
}
EUVIMED